BioLife Solutions Signs Supply Agreement

BioLife Solutions, a developer and manufacturer of biopreservation tools and services for cells, tissues and organs, said Wednesday that it has entered into a supply agreement with Adaptimmune Therapeutics plc (ADAP), clinical-stage biopharmaceutical company.

Adaptimmune Therapeutics develops cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its SPEAR T-cells have shown evidence of tumor reduction in patients as well as a promising risk/benefit profile. BioLife’s CryoStor clinical grade cell freeze media is incorporated into Adaptimmune’s manufacturing process for its SPEAR T-cells.

Leave a Comment